Skip to Main Content

Good morning, everyone, and how are you today? We are doing swell, thank you, helped along by a bright, shiny sun enveloping the chilly Pharmalot campus, where the short person has left for the local schoolhouse and the official mascots are lounging about. We, however, are as busy as ever, quaffing cups of stimulation and foraging for tidbits. Speaking of which, here a few. Hope your day goes well and you conquer the world …

Multiple pharmaceutical executives are expected to add their names to a letter expressing concern about the effects of immigration restrictions on the industry, BioCentury reports. More than 160 biotech industry executives have already signed the letter, which was published earlier this week by Nature Biotechnology and included broader criticism of the implications of the new restrictions for the US.


The Food and Drug Administration has tentatively given its blessing to a key Sanofi manufacturing plant, Bloomberg News reports. The agency “deemed our Le Trait plant to be acceptable,” Sanofi chief executive Olivier Brandicourt told analysts. A formal inspection will take place this quarter. Two new drugs slated for FDA approval this year — for rheumatoid arthritis and a severe form of eczema — are processed at the plant. One approval was already delayed.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!